Could lung cancer prognosis be predicted from a drop of blood?

A blood-based biomarker panel significantly improves lung cancer risk assessment for lung cancer screening. According to new data from researchers at the University of Texas MD Anderson Cancer Center (TX, USA), a blood-based protein panel plus prediction model shows potential to lower lung cancer death by identifying individuals who need CT screening. The only approved screening test for lung cancer is low dose computed tomography (LDCT) and it has been previously reported that LDCT reduces lung cancer mortality by 20%. The US Preventative Services Task Force (USPSTF) recommends yearly screening for those who are between 55–80 years, have a ≥...